Category: Latest News

What’s New in MS Research: January 2020

Latest News, What's New in MS Research January 27, 2020

To live with multiple sclerosis (MS) is to cope with the challenges it presents and to look forward to the promise of ongoing progress in understanding and managing the condition. This edition of “What’s New in MS Research” reflects that mix of obstacles and opportunities.

Read News Article

MSAA Debuts New Logo and Website Design

Latest News January 9, 2020

The Multiple Sclerosis Associa …

Read News Article

FDA Approves Generic Versions of Gilenya®

Latest News December 6, 2019

On December 5, 2019, the United States Food and Drug Administration (FDA) announced that they had approved the applications from three separate pharmaceutical companies for the first generic versions of Gilenya® (fingolimod) capsules for the treatment of relapsing forms of multiple sclerosis (MS) in adult patients.

Read News Article

What’s New in MS Research: November 2019

Latest News, What's New in MS Research November 22, 2019

This edition of MSAA’s “What’s New in MS Research” provides highlights from this year’s European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) annual meeting. Experts from throughout the world gathered in Stockholm, Sweden in mid-September to share and discuss the latest research into the causes, diagnosis, course, and treatment of multiple sclerosis.

Read News Article

Vumerity™ Oral Capsules Approved by the FDA for Adults with Relapsing Forms of MS, Including Active SPMS

Latest News October 31, 2019

On October 30, 2019, Biogen Inc. and Alkermes plc announced the United States Food and Drug Administration (FDA) approval of Vumerity™ (diroximel fumarate) oral capsules to treat adults with relapsing forms of multiple sclerosis (MS). This approval includes the treatment of clinically isolated syndrome (CIS), relapsing-remitting MS (RRMS), and active secondary-progressive MS (SPMS).

Read News Article